Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-25T23:24:37.307Z Has data issue: false hasContentIssue false
  • English
  • Français

Access to Life-Saving Medicines and Intellectual Property Rights: An Ethical Assessment

Published online by Cambridge University Press:  25 March 2011

DORIS SCHROEDER  and
PETER SINGER
Get access Rights & Permissions [Opens in a new window]

Extract

Dying before one’s time has been a prominent theme in classic literature and poetry. Catherine Linton’s youthful death in Wuthering Heights leaves behind a bereft Heathcliff and generations of mourning readers. The author herself, Emily Brontë, died young from tuberculosis. John Keats’ Ode on Melancholy captures the transitory beauty of 19th century human lives too often ravished by early death. Keats also died of tuberculosis, aged 25. “The bloom, whose petals nipped before they blew, died on the promise of the fruit” is how Percy Bysshe Shelley expressed his grief over Keats’ death. Emily Dickinson wrote So Has a Daisy Vanished, being driven into depression by the early loss of loved ones from typhoid and tuberculosis.

Type
Symposium on Global Bioethics
Information
Cambridge Quarterly of Healthcare Ethics , Volume 20 , Issue 2 , April 2011 , pp. 279 - 289
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Shelley, PB. Adonais: An Elegy on the Death of John Keats. 1821; available at http://mural.uv.es/sangis/adonais.htm (last accessed 26 Jul 2010)Google Scholar.

2. Mamunes, G. So Has A Daisy Vanished: Emily Dickinson and Tuberculosis. Jefferson, NC: McFarland & Co; 2007.Google Scholar

3. See, for instance, Lawlor, C. Consumption and Literature: The Making of the Romantic Disease. Basingstoke: Palgrave Macmillan; 2007.CrossRefGoogle Scholar Lawlor examines the influence of tuberculosis on literature from the Renaissance to the Victorian Period.

4. World Health Organization. Tuberculosis; available at http://www.who.int/mediacentre/factsheets/fs104/en/ (last accessed 31 Jul 2010).

5. Leisinger, KM, Schmitt, KM. Access to healthcare and the pharmaceutical sector. Cambridge Quarterly of Healthcare Ethics, this issue, 309–325.Google Scholar

6. Second-line drugs are usually more expensive than first-line drugs and are only used when the latter fail. Likewise, third-line drugs are used when second-line drugs fail.

7. The average online price for the drug in Germany is ε501 for 90 tablets; see http://www.chirurgie-portal.de/medikament/mycobutin-90-st-pfizer-pharma-gmbh-pzn-8669665.html. Because the dosage may vary, it is not possible to say how long 90 tablets will last. However, tuberculosis treatment usually lasts six months and Mycobutin is one of the drugs that can be taken throughout; see http://www.netdoctor.co.uk/infections/medicines/100001775.html.

8. Agence France Press. Tuberculosis most deadly of infectious diseases. May 2010; available at http://www.physorg.com/news193432561.html (last accessed 27 Jul 2010).

9. Sanofi-Aventis press release. Rifapentine is granted orphan drug status by European commission for treatment of tuberculosis. July 2010; available at http://en.sanofi-aventis.com/binaries/20100701_RIFAPENTINE_en_tcm28-28921.pdf (last accessed 27 Jul 2010).

10. Grover A. Promotion and Protection of all Human Rights, Civil, Political, Economic, Social and Cultural Rights, Including the Right to Development, a Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health, 2009, United Nations, A/HRC/11/12, p.6, 7, 28; available at http://www2.ohchr.org/english/bodies/hrcouncil/docs/11session/A.HRC.11.12_en.pdf (last accessed 31 Jul 2010).

11. Rawls, J. A Theory of Justice. Cambridge, MA: Harvard University Press; 1999:3.Google Scholar

12. Brown, BF, ed. The Natural Law Reader. New York: Oceana Publications; 1960.Google Scholar

13. Finnis, J. Natural Law and Natural Rights. Oxford: Clarendon Press; 1980:281.Google Scholar

14. Brecher, B. Torture and the Ticking Bomb. Oxford: Blackwell Publishers; 2007.CrossRefGoogle Scholar

15. See note 11, Rawls 1999.

16. Nozick, R. Anarchy, State, and Utopia. New York: Basic Books; 1974.Google Scholar

17. Jentzsch, C. Patent for a Pig: The Big Business of Genetics, a film, HTTV Production for WDRWestdeutscher Rundfunk; 2006.Google Scholar

18. Canadian Environmental Law Association. Life Patents: The Oncomouse Case, not dated; available at http://www.cela.ca/collections/celacourts/life-patents-oncomouse-case (last accessed 27 Jul 2010).

19. Irwin A. Patent battle over life. Times Higher Education, 1995; available at http://www.timeshighereducation.co.uk/story.asp?storyCode=95686&sectioncode=26 (last accessed 27 Jul 2010).

20. Institute of Science in Society. Europe’s uprising against GMOs and patents on life, 2009; available at http://www.i-sis.org.uk/EuropesUprisingAgainstGMOs.php (last accessed 27 Jul 2010).

21. Rifkin, J. The Biotech Century: Harnessing the Gene and Remaking the World. New York: Jeremy P. Tarcher/Putnam; 1998:43.Google Scholar

22. Wynberg, R, Chennells, R. Green diamonds of the South: An overview of the San-Hoodia case. In: Wynberg, R, Schroeder, D, Chennells, R, eds. Indigenous Peoples, Consent and Benefit Sharing. Berlin: Springer; 2009:89–124.CrossRefGoogle Scholar

23. One might argue that the issue is actually much more complex, given the restraints imposed on patent applicants by the Convention on Biological Diversity (CBD). However, this does not concern the clash between property and intellectual property rights under discussion. In fact, one could even argue that one of the main results of the CBD is that it prioritizes physical property rights over intellectual property rights by legislating for nonhuman genetic resources to fall under the national sovereignty of states.

24. Murphy M. The natural law tradition in ethics. In: Stanford Encyclopedia of Philosophy, 2008, online resource; available at http://plato.stanford.edu/entries/natural-law-ethics/ (last accessed 27 Jul 2010).

25. Aquinas, T. Summa Theologica: Of the Various Kinds of Law, 1947 [1274]Google Scholar; available at http://www.sacred-texts.com/chr/aquinas/summa/sum229.htm (last accessed 27 Jul 2010).

26. May, W. Contemporary perspectives on Thomistic natural law. In: Goyette, J, Latkovic, M, Myers, R, eds. St. Thomas and the Natural Law Tradition. Washington, DC: The Catholic University of America Press; 2004:138–84Google Scholar, at p. 132.

27. Aquinas, T. Summa Theologica: Of the Natural Law, 1947 [1274]Google Scholar; available at http://www.sacred-texts.com/chr/aquinas/summa/sum232.htm (last accessed 27 Jul 2010).

28. Aquinas, T. Summa Theologica: Of Theft and Robbery, 1947 [1274]Google Scholar; available at http://www.sacred-texts.com/chr/aquinas/summa/sum322.htm (last accessed 27 Jul 2010).

29. See note 28, Aquinas 1947 [1274].

30. Locke, J. Two Treatises of Government, Book 1. London: Thomas Tegg, W. Sharpe and Son; 1823:31Google Scholar; available at http://socserv.mcmaster.ca/econ/ugcm/3ll3/locke/government.pdf (last accessed 27 Jul 2010).

31. This section draws heavily on Pogge, T, Hollis, A. The Health Impact Fund: Making New Medicines Accessible to All. Incentives for Global Health; 2008:52–4Google Scholar; available at http://www.yale.edu/macmillan/igh/# (last accessed 27 Jul 2010).

32. See note 10, Grover 2009:28.

33. From Pogge, T, Schroeder, D. Why we need a new approach to pharmaceutical innovation: A pragmatic answer to a moral question. In: Noppen, M, Wynants, M, eds. In Sickness and Health: The Future of Medicine. Brussels: Vrije Universiteit Brussel Press; 2009:197–213Google Scholar, at p. 202.

34. Grover uses the term differently, in all likelihood referring to the nonavailability of generic drugs.

35. Selgelid, M, Sepers, EM. Patents, profits, and the price of pills: Implications for access and availability. In: Illingworth, P, Schuklenk, U, Cohen, JC, eds. The Power of Pills: Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing Policies. London: Pluto Press; 2006:153–63Google Scholar, at p. 153.

36. Schroeder, D. Does the pharmaceutical sector have a coresponsibility for the human right to health? Cambridge Quarterly of Healthcare Ethics, this issue, 298–308.Google Scholar

37. See note 10, Grover 2009.

38. Incentives for Global Health Web site available at http://www.yale.edu/macmillan/igh/ (last accessed 27 Jul 2010).

39. Pogge, T. The Health Impact Fund: Boosting pharmaceutical innovation without obstructing free access. Cambridge Quarterly of Healthcare Ethics 2009;18(1):78–86CrossRefGoogle ScholarPubMed. Pogge, T. The Montréal Statement on the Human Right to Essential Medicines. Cambridge Quarterly of Healthcare Ethics 2007;16:97–108.CrossRefGoogle ScholarPubMed

40. Pang, T. Developing Medicines in Line with Global Public Health Needs: The Role of the World Health Organization. Cambridge Quarterly of Healthcare Ethics, this issue, 290–297.Google Scholar